|Day Low/High||61.88 / 62.58|
|52 Wk Low/High||47.97 / 64.00|
Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
These dividend stocks are poised to increase their payouts to shareholders soon.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will host a teleconference for investors following the presentation of data at the European Society for Medical Oncology (ESMO) 2016 Congress in...
Allegations that Merck breached patents on diabetes blockbuster Lantus looks like a replay of Sanofi's 2015 case against Eli Lilly.
U.S. stock futures point higher as oil prices rally; Canada's autoworkers' union and GM make little progress in contract talks ahead of a Monday deadline.
Merck (MRK) and Pfizer's (PFE) diabetes treatment met its primary endpoint in a Phase III trial.
Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2015/2016 global corporate responsibility report.
Zoetis is selling a lineup of drugs for dogs, and that looks to mean big business.
Zoetis is not averse to a little noise as investors, analysts take notice.
From Altria to Western Union, these 21 companies have must-own dates over the next week.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.
Merck's (MRK) lung cancer drug, called Keytruda, was given breakthrough therapy status by the FDA.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.
Merck has decided to discontinue the development of its osteoporosis drug and will not seek regulatory approval for its use.
Merck (MRK) will no longer develop its osteoporosis treatment due to an increased risk of stroke.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck's investigational cathepsin K inhibitor for osteoporosis, and will not seek...
Each of these companies pays extremely safe dividends, yields over 2%, and doesn't appear to be extremely overvalued like many other dividend-paying stocks in the market today.
Merck (MRK) could remain the leader in lung cancer treatments depending on how it 'plays its hand,' Bernstein said in a note Wednesday.
So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.
The tactic is a slightly out-of-the-money, bearishly biased vertical put spread expiring in November.
The market continues to defy those players who believe we are seeing the calm before the storm.
The FDA approved Merck's Keytruda, a drug to treat metastatic and recurrent cancer.
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.